The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cellmid (CDY) has received import permits allowing the sale of its Jo-Ju and Lexilis-branded shampoos in mainland China
  • Based in Sydney, Cellmid is a health and beauty company leveraging innovative anti-aging technologies
  • The permits, issued by the Chinese National Medical Products Administration, are essential for the sale of fully finished products in China
  • The documents allow CDY to progress its 10-year distribution deal with Ourui Health Management
  • Cellmid shares are up 2.94 per cent, trading at 7 cents each

Cellmid (CDY) has received import permits allowing the sale of its Jo-Ju and Lexilis-branded shampoos in mainland China.

Based in Sydney, Cellmid is a health and beauty business leveraging innovative anti-aging technologies.

The permits, issued by the Chinese National Medical Products Administration (NMPA), are essential for the sale of fully finished products in China.

Cellmid says the receipt of the documents is a key milestone in implementing its 10-year distribution agreement signed with Ourui Health Management in December last year.

The permits do not have an expiry date and will remain valid subject to Cellmid’s compliance with NMPA’s annual reporting requirements.

On the market this afternoon, Cellmid shares are up 2.94 per cent, trading at 7 cents at 1:17 pm AEST.

CDY by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system